Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.33 |
---|---|
High | 15.61 |
Low | 14.94 |
Bid | 14.97 |
Offer | 15.46 |
Previous close | 15.30 |
Average volume | 1.06m |
---|---|
Shares outstanding | 91.04m |
Free float | 89.20m |
P/E (TTM) | -- |
Market cap | 1.39bn USD |
EPS (TTM) | -1.30 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
- Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
- Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
- Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
- Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
- Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
- Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
- Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
- Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
- Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
More ▼